March 16, 2018

March 16, 2018

TBBJ names 2018 Top Corporate Counsel of the year

Tampa Bay Business Journal – March 15

David de la Parte, executive vice president and general counsel for Moffitt Cancer Center, was named the Top Corporate Counsel of the year by the Tampa Bay Business Journal. de la Parte also won in the nonprofit category.

Ernest Hooper: Chuckle at my workout, sure, but don’t miss Men’s Health Forum

Tampa Bay Times – March 15

Since the forum coincides with Moffitt’s Colorectal Awareness Event, they want men and women to walk through the inflatable colon. Not every walk has to be romantic, if it saves your life.

Combination Therapies Approaching the Advanced RCC Treatment Paradigm

Targeted Oncology – March 15

Mayer Fishman, MD, PhD, a medical oncologist specializing in genitourinary oncology at Moffitt Cancer Center in Tampa, Florida, sees these developments as positive for both patients and physicians. 

Here’s What to Expect Before, During, and After an MRI

SELF Magazine – March 15

In most cases, you’ll make an appointment to have your scan done and just show up with zero prep work, Kerry L. Thomas, M.D., a radiologist at Moffitt Cancer Center, tells SELF. 

Researchers use single-cell imaging and mathematical modeling to determine effective drug properties

 BrinkWire – March 15

“Clinical success or failure of targeted therapy depends heavily on whether the drug molecules are able to reach all tumor cells and engage with their molecular targets to invoke the desired therapeutic effect,” said Kasia A. Rejniak, Ph.D., associate member of the Department of Integrated Mathematical Oncology at Moffitt. 

Samaritan Services offers rides to seniors who can’t or shouldn’t drive

The Observer News – March 15

Currently there are six vehicles reserved for this service, which transports riders to places like Moffitt Cancer Center, Tampa General Hospital, Florida Orthopedic offices, the VA Hospital or Lighthouse for the Blind in Tampa and the VA clinic in Bradenton.

Will There Be a Vaccine for Breast Cancer Someday?

US News and World Report – March 14

Dr. Brian Czerniecki, chair and senior member in the Moffitt Cancer Center Department of Breast Oncology in Tampa, has also been working on developing a vaccine for HER2-positive breast cancer and is currently conducting a clinical trial to determine the efficacy of a vaccine that’s made from a patient’s own white blood cells.


M2Gen manages tissue and clinical data collection from patients enrolled in the Total Cancer Care Protocol, a research study operated by the H. Lee Moffitt Cancer Center and Research Institute in collaboration with ORIEN's cancer center members.

Colorectal Cancer: What is It and How to Prevent It

Orlando Medical News – March 14

Leena Kamat, MD, is a board certified diagnostic radiologist, sub-specialized in breast imaging for Radiology Specialists of Florida at Florida Hospital. She earned her medical degree at the University of Florida, College of Medicine and following graduation completed her residency at the University of South Florida and a fellowship in breast imaging at the Moffitt Cancer Center.

Overview of Somatostatin Analogs for NETs

OncLive – March 14

Jonathan R. Strosberg, MD: There are 2 commercially available somatostatin analogs in gastroenteropancreatic neuroendocrine tumors—octreotide (Sandostatin) and lanreotide (Somatuline). 

ALL: Therapy for Post-Induction MRD-Positivity

OncLive – March 14

Bijal D. Shah, MD: I think this harkens back to what you said earlier. The problem is we keep talking about MRD as though it’s different from remission. Really, it’s not, and what we need to do is refine our response criteria.

Researchers use novel methods to determine drug uptake for tumours

European Pharmaceutical Review – March 14

Researchers at the Moffitt Cancer Center in Florida have combined single-cell imaging of cancer cells in mice with mathematical modelling to establish which drug characteristics determine its efficacy.

ImmunoRestoration Announces Exclusive License to Immunotherapeutic Cancer Vaccine Platform from the University of Pennsylvania – March 14

After more than ten years of research and use in more than 100 breast cancer patients, Dr. Czerniecki, now Chair and Senior Member in Department of Breast Oncology of the Moffitt Cancer Center in Tampa, Florida, and Dr. Koski, currently at Kent State University, remain convinced the platform holds the possibility of being a breakthrough treatment.

Metallic stents efficacious for malignant ureteral obstruction

Urology Times – March 13

The stents offer "excellent treatment outcomes and improved cost effectiveness," said study co-author Philippe E Spiess, MD, MS, of Moffitt Cancer Center and the University of South Florida, Tampa. Also posted to Medical Health News

FDA Approves New Treatment for Some Types of Neuroendocrine Tumors

Everyday Health – March 13

Lutathera was approved based on a randomized, clinical trial of 229 patients led by Jonathan Strosberg, MD, an associate member of the gastrointestinal oncology department at Moffitt Cancer Center in Tampa, Florida. 

University Mall developers buy Sears box, announce mall's new name

Tampa Bay Business Journal – March 13

Despite the presence of economic engines like H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida, the mall and surrounding areas have not come together as a cohesive neighborhood.

10 Top Cancer Experts Reveal What They Do to Prevent the Deadly Disease

MSN Health & Fitness – March 13

A diet rich in vegetables, fiber, and omega-3 fats can curb inflammation and help fight cancer. Philippe Spiess, M.D., a genitourinary oncologist at Moffitt Cancer Center, eats what he calls a “power egg breakfast wrap.”

Researchers use single-cell imaging and mathematical modeling to determine effective drug properties

Medical Xpress – March 13

In a new study published in Scientific Reports, Moffitt Cancer Center researchers combined single-cell imaging of cancer cells in mice with mathematical modeling to determine which drug characteristics are the most important for efficient drug uptake. Also posted to,, The Jersey Tribune, Tampa Dispatch, Science Codex

HPV is causing an oral cancer epidemic in men by outwitting natural defenses

Orlando Sentinel – March 12

How could this be? Anna R. Giuliano, the researcher at the Moffitt Cancer Center in Tampa, Fla., who led the HIM study, said recurring infections may be due to reactivation of dormant virus, or to auto-inoculation the man spreads infection from one part of his body to another. Or to something else entirely.

Dr Monica Taylor — An advocate for multiple myeloma awareness

The Jamaican Observer – March 12

As a result, Dr Taylor went through a course of chemotherapy treatment to reduce the myeloma and in 2012 she went to Moffitt Cancer Centre in Tampa, Florida, where she did a stem cell transplant.

Urban Café talks about the Men’s Health Forum

WMNF FM – March 11

Dr. B. Lee Green discusses the upcoming Men’s Health Forum on WMNF’s Sunday morning show, Urban Café.

Acute Lymphoblastic Leukemia: Optimizing MRD Testing

OncLive – March 9

Bijal D. Shah, MD: Although it wasn’t as relevant, there were still patients who relapsed despite being MRD-negative at 3 months. But when they compared the MRD-negative versus the MRD-positive patients, the MRD-positive patients clearly did much worse.

The diagnosis of early T-cell precursor (ETP) ALL

Oncology Tube – March 9

Our knowledge of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is advancing, as highlighted by an excellent talk on the topic at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL. Speaking from the meeting, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses his thoughts on the diagnosis of ETP-ALL. 

The role of MRD in ALL: what defines a complete response?

Oncology Tube – March 9

Now that our techniques to measure minimal residual disease (MRD) are highlighly sensitive, the utility of MRD to guide and measure response to treatment can be brought into effective action. In this interview, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, gives an interesting perspective on the role of MRD in acute lymphoblastic leukemia (ALL).

How should we utilizing molecular data to improve ALL treatment?

Oncology Tube – March 9

Certain molecular lesions are inherently targetable in acute lymphoblastic leukemia (ALL); patients with these changes should be given access to therapy that specifically targets these lesions. Speaking from the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses how clinicians should be utilizing molecular data to improve treatment, giving a case-based example to poignantly highlight his point.

We know that MRD is relevant, what next?

Oncology  Tube – March 9

It is now widely agreed that minimal residual disease (MRD) is a clinically relevant measure, so how can we now move forward to achieve the widespread utilization of MRD measurement in a meaningful way? This question is explored here, in an interesting discussion with Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Dr Shah raises the topic of what we should now define as complete and partial response rates, and whether we should still be using these terms. 




Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.